The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.

Item

http://www.wikidata.org/entity/Q37078647

Q37078647

about

Cardiotoxicity in childhood cancer survivors: strategies for prevention and management Cardiac toxicity in cancer survivors Dexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in Mice Collaborative Research in Childhood Cancer Survivorship: The Current Landscape Prediction of cancer drugs by chemical-chemical interactions Cardiovascular disease in adult survivors of childhood cancer.Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients Dexrazoxane abrogates acute doxorubicin toxicity in marmoset ovary Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian cells.Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer.Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group.Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncolog Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia Children's Oncology Group's 2013 blueprint for research: survivorship and outcomes.Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice.An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies.Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity.Treatment-related cardiotoxicity in survivors of childhood cancer.Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment.Cardiovascular prevention in the cancer survivor.Cardiac complications in childhood cancer survivors treated with anthracyclines.Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments.Prevention of cardiotoxicity among survivors of childhood cancer.Late Cardiotoxicity: Issues for Childhood Cancer Survivors.Chemotherapy-induced cardiotoxicity in children.Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).Cardiotoxicity in childhood cancer survivors: a problem with long-term consequences in need of early detection and prevention.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.Cardiometabolic Risk Factors in Childhood, Adolescent and Young Adult Survivors of Acute Lymphoblastic Leukemia - A Petale Cohort.Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors.The Role of HSP40 Conserved Motifs in the Response to Cytotoxic Stress.Administration of Dexrazoxane Improves Cardiac Indices in Children and Young Adults With Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes.

P2860

Q24628695-584815B8-F156-4C8D-B26D-719FA9498D02 Q26851957-7E7EB271-067D-47E4-B897-507A99D57891 Q27345163-9D613EFC-80C0-4E53-8A7B-4DB7FFC516A9 Q28081135-4294FE74-AA21-449E-924F-0A0CAB352C39 Q28539449-9FA397E9-F002-4817-A9BC-29E3F5EA8F54 Q34042984-2CA79C23-B3E6-4A10-9C8C-312C0AD3A1BD Q34253158-EF797EB7-2B16-4294-ACAC-E5DBE12D4DC2 Q35201332-1BC686A4-0264-463E-823B-617A26D05ECA Q35562745-D9B1DEC1-0975-4482-8B5B-3B23E8A2274A Q35849444-E0035618-D915-4DFD-8F8E-5C4BEEE393E0 Q35862550-9867F232-9F2C-4DE7-A43A-3341033ABD18 Q35947024-220EFE3D-F483-4277-B5B2-8D2F207A49FC Q36099606-B042ABFE-48BD-4913-BD61-3A79AD35D3DD Q36184665-15288EFC-BEEC-42B7-BF7C-52D418256F8C Q36309826-94DD3C89-4EF5-4019-9AC1-761E41427B59 Q36653789-B2152BB9-B005-47BD-AE50-105DDE296D40 Q36914391-C94DDF75-3769-4CD9-B91F-67CC1D7D9CBF Q37209968-786C03A9-F83D-4C4C-85A8-0ED5A5AB6B10 Q37237505-E3B41E0F-A74E-4C5E-A687-C474A8B5574A Q37569911-A921637C-D345-4D85-9B23-2A4109F9C460 Q37613120-A8DECB54-FC07-4024-8AE6-87B522ED6246 Q38109236-D15AD0E2-36F2-4C01-895F-FDF0455AB583 Q38148968-D4315AE6-730A-4567-B8D4-81436A26683D Q38156036-0335D5D5-17B8-4346-A730-F243EA6D0656 Q38205702-E392114B-FAE5-4BE6-967B-D49190603EEE Q38338228-B76F946C-ACAE-4FCF-857A-EA4621EE51DF Q38588167-888D022D-7619-4B02-AB91-24A06C40C806 Q38786052-0A0CBDAE-BE49-4A92-ADEE-2ADC44D569E7 Q38824644-0179B956-BF85-4BC6-8E04-AAAE86B9DF01 Q38845457-0523781A-730D-4F98-BF3B-F26B19BED1BF Q39415815-4659EBDC-68D9-4A36-9D4A-182E0153590B Q41002762-98DB4F55-028C-41BA-B031-5D01E31DE48B Q43983538-4F9A5039-FEE8-4A4A-8666-D11415837A44 Q45073135-46F57DDD-795D-4C2B-9AAC-46BE7CC0C1FC Q47118957-EB48C3E6-74F4-4D7E-829A-D616D244DA8B Q51105427-F811A4B9-1935-486D-911D-88678F6D2967 Q55024465-7E22EE86-808D-4276-9346-C0034E4EBA54 Q55387303-927DF0BA-3393-47AE-8258-A07C791117B0

P2860

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.

Item

http://www.wikidata.org/entity/Q37078647

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 April 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs